Curative and organ-preserving treatment with intra-arterial carboplatin induction followed by surgery and/or radiotherapy for advanced head and neck cancer: single-center five-year results.
BMC Cancer
; 7: 62, 2007 Apr 11.
Article
en En
| MEDLINE
| ID: mdl-17428336
ABSTRACT
BACKGROUND:
This study evaluated the feasibility, toxicity, response rate and survival of neoadjuvant superselective intra-arterial infusion of high dose carboplatin in advanced head and neck cancer.METHODS:
Forty-six patients with primary head and neck squamous cell carcinoma received 3 cycles of intra-arterial carboplatin (300 to 350 mg/m2 per cycle every 2 weeks), followed by radiotherapy or surgery plus radiotherapy.RESULTS:
No complications or severe toxicity occurred. Sixteen patients (35%) were complete responders, 20 (43%) partial responders while 10 (22%) did not respond to treatment. After completion of the multimodality treatment, 38/46 patients (83%) were complete responders. After a 5-year follow-up period, 18/46 patients (39%) are alive and disease-free, 3 (6,5%) have died of a second primary tumor and 25 (54.5%) have died of the disease.CONCLUSION:
Intra-arterial carboplatin induction chemotherapy is a safe, well-tolerated technique that discriminates between responders and non-responders and so may have prognostic significance in planning further integrated treatments aimed to organ preservation for advanced head and neck carcinomas.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Escamosas
/
Carboplatino
/
Neoplasias de Cabeza y Cuello
/
Antineoplásicos
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Idioma:
En
Revista:
BMC Cancer
Asunto de la revista:
NEOPLASIAS
Año:
2007
Tipo del documento:
Article